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Topic Signiﬁcance & Study Purpose/Background/Rationale:
The success of allogeneic hematopoietic cell transplantation
(AlloHCT) continues to be limited by the incidence of acute
graft-versus-host disease (aGVHD), a serious and sometimes
fatal complication. Steroid-refractory aGVHD (SR-aGVHD)
that is unresponsive to initial therapy with glucocorticoste-
roids has a 40% response rate to second line agents. Inter-
leukin-6 has been implicated in the pathogenesis of aGVHD.
Tociluzimab (TCZ) is an anti IL-6 monoclonal antibody and, to
our knowledge, has not been previously reported for the
treatment of aGVHD in children.
Methods, Intervention, & Analysis:We present a 3 year-old
boy with a history of sickle cell disease who received a 7/8
matched unrelated donor AlloHCT. On day + 35, he was
diagnosed with Grade IV intestinal aGVHD by both patho-
logic and clinical criteria. Symptoms included an ileus, stool
output >1 liter/m2/day, persistent abdominal pain, and
hematochezia. His abdominal pain was not controlled by
escalating doses of either hydromorphone or fentanyl.
Moderate relief was demonstrated with the combination of a
ketamine drip and methadone. Initially the patient received
methylprednisolone (2mg/kg/day), but was determined to be
SR-aGVHD with worsening symptoms. He subsequently
received multiple anti-GVHD agents at different time points,
including mesenchymal stem cells, etanercept, basiliximab
in combination with inﬂiximab, pentostatin, and anti-
thymocyte globulin. Despite these efforts, the patient
exhibited no change in either symptomatology or histology.
Approximately 2months after the initial diagnosis of aGVHD,
interleukin-6 levels were demonstrated to be 100 times the
upper limit of normal. Salvage therapywith TCZwas initiated
at a dose of 8mg/kg weekly for three weeks and then every
other week for three subsequent doses. Within three weeks
of the initiation of TCZ therapy, the patient showed an
improvement in stool output and abdominal pain, subse-
quently narcotic were weaned off successfully. Eight weeks
after discontinuation of TCZ, the patient developed a recur-
rence of abdominal pain and an intestinal biopsy was posi-
tive for grade I aGVHD. TCZ therapy was reinitiated on an
every other week basis for four doses and a complete
remission of aGVHDwas achieved. At the time of writing this
report, the patient no longer exhibits signs or symptoms of
aGVHD and is in the process of being discharged after a
9-month hospitalization.
Findings & Interpretation: In the literature to date, there is
just one case report of the use of TCZ in an adult with SR-
aGVHD. An appropriate dose and schedule has not been
established. Due to the severity of this child’s disease and
demonstrated lack of response to conventional therapies, we
utilized TCZ as a salvage therapy and found it to be well
tolerated and potentially life saving.
Discussion & Implications: Though our ﬁndings consist of
this single patient, the dramatic improvement noted may
demonstrate potential efﬁcacy of TCZ in children with
SR-aGVHD.483
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Topic Signiﬁcance & Study Purpose/Background/Rationale:
Limited data exists to determine the most appropriate con-
version factor from IV to PO administration of tacrolimus in
children receiving tacrolimus for aGVHD prophylaxis
following AlloHCT. The incidence and impact of sub-thera-
peutic tacrolimus levels after conversion from IV to PO is also
not well described.
Methods, Intervention, & Analysis: We retrospectively
studied the association between length of time to achieve
therapeutic tacrolimus levels (deﬁned as >10ng/ml x 2 days)
after conversion from IV to PO using the currently accepted
factor of 4:1, as well as the incidence of grades I-IV aGVHD.
aGVHD prophylaxis consisted of mycophenolate mofetil and
tacrolimus. Tacrolimus was initiated at a dose of 0.03 mg/kg/
day as a continuous IV infusion. The dose was adjusted to
maintain trough levels within the range of 10-20 ng/mL.
Once patients were able to tolerate oral medications they
were transitioned to PO tacrolimus. Patients were kept in the
hospital until they achieved therapeutic tacrolimus levels on
PO. Patients were excluded if tacrolimus was initiated as IV
and was never transitioned to PO or if they were started on
PO and remained on PO for the duration of therapy.
Findings & Interpretation: Eighty-nine children (mean age,
8.3 yrs; range, 0.25-22: 60M/29F) undergoing AlloHCT for
malignant (n¼ 52, 58.4%) and nonmalignant (n¼37, 41.6%)
disorders between March 2005 and April 2012 were identi-
ﬁed. The overall incidence of Grade I-IV aGVHDwas 48.3%. At
the time of diagnosis of aGVHD, 20 patients (46.5%) were on
IV tacrolimus, and 23 patients (53.5%) were on PO tacrolimus.
Patients were transitioned to oral tacrolimus at a median of
23 days post-AlloHCT. After conversion to PO tacrolimus, the
median and mean number of days to reach a therapeutic
level was 7 and 10.2d (range 0-61), respectively. We
compared the mean number of days to achieve therapeutic
levels between those patients who developed aGVHD (n¼43,
12.6 days) and those who with no aGVHD (n¼46, 8.1 days),
demonstrating that patients diagnosed with aGVHD took on
average 4 days longer to achieve therapeutic levels on oral
tacrolimus, which was statistically signiﬁcant p¼0.026
(t-test). Patients â&U 12 yrs (n¼31) when compared to pa-
tients <12 yrs (n¼58) took a signiﬁcantly longer time to
achieve therapeutic levels (12.8 vs. 8.8 days t-test, p¼0.05)
after conversion from IV tacrolimus to PO. There was no
signiﬁcant association found between prior diagnosis of
aGVHD and number of days required to obtain therapeutic
tacrolimus levels.
Discussion & Implications: In conclusion, this data suggests
that the longer a patient takes to achieve therapeutic tacro-
limus levels after transitioning to PO, the greater their risk for
developing aGVHD. Further analysis is ongoing to identify
speciﬁc risk factors and patient populations who take longer
than the median number of days to achieve therapeutic
tacrolimus levels. This analysis may identify patients who
